DTs-ll is a highly diphtheria toxin (DT)-sensitive cell line previously isolated by transfection of wildtype DT-resistant mouse L-M(TK-) cells with the cDNA encoding a monkey Vero cell DT receptor. DTs-II (Mr 37,195). The cytotoxic action ofDT occurs by the following steps: (i) binding to specific cell-surface receptors, (ii) internalization of the (toxin-receptor) complexes into vesicles, and (iii) translocation of the A fragment from acidified vesicles into the cytosol, where it inhibits protein synthesis by ADP-ribosylation of elongation factor 2 (1-3).
growth factor (HB-EGF) (6, 7) . In addition, we isolated a stable DT-sensitive (DTs) mouse cell line (DTs-II) by transfection of L-M(TK-) cells with the cloned receptor cDNA (4) . The DTs-II cells (i) are as highly toxin-sensitive [concentration of DT that results in 50%o inhibition of protein synthesis (ICso) w5 ng/ml] as Vero cells, one of the most toxin-sensitive cell lines (8) , and (ii) display =z3-fold more specific toxin receptors (=50,000 vs. %20,000) than Vero cells [which have the largest receptor density of any known cultured cells (9) ] but with "40-fold lower affinity than Vero cell receptors.
Mekada's laboratory isolated a monoclonal antibody that protected Vero cells from DT-mediated cytotoxicity (10) . More recently they cloned a gene whose expressed cellsurface product (Mr ==27,000) is recognized by this monoclonal antibody (11) . The deduced amino acid sequence of this protein revealed it to be the monkey homologue of the human CD9 antigen. Interestingly, transfection of mouse L-M(TK-) cells with the cDNA encoding CD9 did not result in DTs mouse cells, suggesting that CD9 is not a DT receptor per se. However, CD9 transfection of moderately toxin-sensitive human-mouse hybrid cells possessing human chromosome 5 [believed to encode the human DT receptor (12) ] resulted in increased toxin sensitivity. The number of toxin-binding sites per cell increased from 500 (in the human-mouse hybrid cells) up to 2600 (in the most toxin-sensitive CD9 transfectant), a level of receptor density significantly below that displayed on the surface of Vero cells (4, 9, 11) . Furthermore, there appeared to be a correlation between quantity of CD9 expressed on different cell lines and toxin sensitivity (10, 11) .
It was therefore of interest to investigate whether transfection of the already highly toxin-sensitive DTs-II mouse cells with the gene encoding the monkey CD9 homologue would result in (i) a further increase in toxin sensitivity, (ii) a further increase in the number of DT receptors, and/or (iii) the expression of a class of receptors having an increased toxin affinity comparable to that ofVero cells. We (4) were employed for the cotransfection experiment. Cotransfection of pCD9 and pHyg DNA was performed as described by Graham et al. (16) . Supercoiled DNA of pCD9 and pHyg was used at 2 ,ug/ml and 0.1 ug/ml, respectively; sonicated salmon sperm DNA (1 pg/ml) was used as nonspecific carrier DNA.
Selection for hygromycin-resistant (HygR) transfectants was accomplished in culture medium (Dulbecco's modified Eagle medium containing 10lo fetal bovine serum, 50 units of penicillin per ml, 50 pg of streptomycin per ml, 2.5 .g of amphotericin B per ml, and 2 mM L-glutamine) supplemented with 1 mg of hygromycin B per ml (selection medium). L-M(TK-)/CD9/HygR cells were isolated and purified directly from the transfection plates, whereas the DTs-II/CD9/ HygR cells were purified employing a replica plate system (as described below).
Isolation of L-M(TK-)/CD9 cells. HygR cells were removed from the L-M(TK-) transfection plates by overlaying colonies with BBL blank paper discs saturated with trypsin. The discs were then transferred to six-well plates containing selection medium. The cells were initially screened for CD9 expression by ELISA, employing anti-CD9 IgG (as described below). CD9-positive cells were further purified by the isolation and propagation ofcells from single colonies. Each subsequent cell population was screened employing the ELISA until no further enrichment of CD9 expression was obtained. A purified stable cell line, L-M(TK-)/CD9, obtained in this fashion, was employed in additional ELISA experiments to quantify the concentration of CD9 on the cell surface.
Isolation of DTs-H/CD9 Transfectants. Isolation of DThypersensitive DTS-II/CD9 cells proceeded through the use of the replica plate system previously described (4, 5, 13), with slight modifications. Briefly, HygR colonies were overlaid with PeCap membranes and incubated at 37°C in 5% CO2 for 7 days. This allowed the cells to grow into the PeCap membranes, producing a replica of the colonies present on the transfection plate. One membrane was utilized to screen for the presence of colonies hypersensitive to DT by assaying for inhibition of [35S]methionine incorporation into protein.
The assay was modified in the following fashion: rather than incubating the PeCap membranes with DT at 2 jg/ml for 18 hr, they were incubated with 0.01 ,g/ml for 1.5 hr, conditions under which DTs-II cells appear to be resistant to DT. Cells from a DT-hypersensitive colony were subsequently subcultured and purified twice with the modified replica plate system. A purified DTs-II/CD9 stable cell line (DTs-III) was employed for all subsequent experiments. Except for the fact that DTs-III cells grow slightly slower than DTs-II cells, they do not appear different than DTs-II cells by light microscopy.
Quantification of CD9 by ELISA. To screen for CD9, a whole cell ELISA was developed. Briefly, 96-well plates were seeded at 4 x 104 cells per well. After overnight incubation at 37°C in 5% C02, the medium was removed and the cells were fixed in a 10% formalin solution for 45 min at 4°C. The monolayers were washed three times with phosphate-buffered saline containing Tween 20 (PBST; 8.8 mM Na2HPO4/1.2 mM KH2PO4/140 mM NaCl/10 mM KCI/ 0.05% Tween 20, pH 7.4) . To prevent nonspecific adsorption, the monolayers were incubated with blocking solution (PBST containing 0.2% bovine serum albumin) for 1 hr at 4°C. The monolayers were washed once in PBST and then incubated for 1 hr at 4°C with a 1:1000 dilution of anti-CD9 IgG in blocking solution. Following three additional washes in PBST, the monolayers were incubated for 1 hr at 4°C with a 1:1000 dilution (in blocking solution) of horseradish peroxidase-conjugated goat anti-mouse IgG. The monolayers were washed three times with PBST and incubated with 50 pl of substrate solution per well (3 mM o-phenylenediamine dihydrochloride in 0.66 M Na2HPO4/0.347 M citric acid/0.01% H202, pH 5.0). The colorimetric reaction was followed by measuring the change in absorbance at 490 nm. To confirm the cell densities, three control wells per plate were trypsinized and the number of cells per well was determined. The change in absorbance per cell was calculated and plotted vs. time (min); the change in absorbance per cell per min was calculated from the linear portion of the graph.
Cytotoxicity Assay. The ability of DT to inhibit protein synthesis was determined by assaying for the incorporation of [3H]leucine into trichloroacetic acid-precipitable material as described (17, 18).
DT-Binding Assay. DT binding was performed as described (4, 5) , except that the cells were preincubated for 30 min with ice-cold binding medium (medium 199, 50 ,ug ofbovine serum albumin per ml, 100 ,ug of gelatin per ml, and 20 mM Hepes, pH 7.4) prior to the addition of 125I-labeled DT. In addition, three control wells per tissue culture dish were trypsinized and the number of cells was determined; all binding data were then normalized per S x 104 cells.
Cross-Linking of Radiolabeled DT Bound to Cells. Chemical cross-linking of DT to cell-surface proteins was performed according to the methods previously described (4, 14) , except that the cells were preincubated for 30 min with ice-cold binding medium prior to the addition of 125I-labeled DT.
RESULTS AND DISCUSSION
Isolation of DT-Hypersensitive Mouse Cells. In the present studies, we wanted to determine whether expressing the Vero cell CD9 antigen in highly toxin-sensitive DTs-II cells would increase the sensitivity of these cells to DT. A modification of the replica plate system previously described (4, 5, 13) Binding of Radiolabeled DT to Cell-Surface Receptors of DTs-M Cells. In the present studies DTs-III cells were found to be hypersensitive to DT. To determine whether the increased sensitivity is due to an increase in the number of receptors and/or to the expression ofa class ofreceptors with higher affinity for DT, the cells were assayed for their ability to bind 125I-labeled DT, and the data were subjected to Scatchard analyses. DTs-III cells were found to bind 125I. labeled DT in a highly specific and saturable manner (Fig.  1C) . Typically, the level of nonspecific binding in these cells was <10% of the total binding. This is in contrast to the level of nonspecific binding (20-30%) observed in DTs-II cells (Fig. 1B) . The extent of specific binding of 125I-labeled DT obtained with DTs-III cells was =20-fold greater than that obtained with DTs-II cells and =40-fold greater than that obtained with Vero cells (Fig. 1) . Scatchard analyses demonstrated that DTs-III cells express 1,040,000 receptors per cell, with an apparent Kd of 1.8 x 10-8 M (Fig. 1C Inset) , whereas DTs-II cells possess 48,000 receptors per cell, with an apparent Kd of 1.5 x 10-8 M (Fig. 1B Inset) . In contrast, Vero cells express 18,000 receptors per cell, with an apparent Kd of 1.2 x 10-9 M (Fig. 1A Inset) -86,000 (I), -82,000 (II), and -70,000 (III) (Fig. 2A, lanes 1  and 3) . These proteins correspond (by difference) to three toxin-binding proteins with Mrs of =26,000 (I), =22,000 (II), and =10,000 (III). Importantly, the addition of a 100-fold excess unlabeled DT during the binding of 125I-labeled DT completely inhibited the appearance of these bands ( Fig. 2A,  lanes 2 and 4) , demonstrating the specificity of binding of 17-5I-labeled DT to DT-binding proteins. When the same crosslinked extracts were analyzed under reducing conditions, the major DT band had a M, of -58,000. The high molecular weight, cross-linked proteins had Mrs of -86,000 (I), %78,000 (II), and "'70,000 (III) (Fig. 2A, lanes 5 and 7) . These results are consistent with DT-binding proteins having Mrs of --28,000, -20,000, and =z12,000, respectively.
Similar analyses were performed with Vero and DTs-III cell extracts (Fig. 2B) . Under nonreducing conditions, the major DT band had a M, of =58,000, and similar cross-linked protein profiles were observed between Vero and DTs-III cells. The appearance of the cross-linked proteins could be inhibited in the presence of a 100-fold excess unlabeled DT. The high molecular weight bands observed in extracts of DTs-III and Vero cells included proteins having Mrs of ==80,000 (I), %72,000 (II), and =66,000 (III) (Fig. 2B, lanes 1  and 3) . These correspond to DT-binding proteins having Mrs of --22,000, =14,000, and -"8000, respectively. Under reducing conditions, the major DT band had a Mr of -58,000 and the high molecular weight proteins in DTs-III and Vero cell extracts had Mrs of "'82,000 (I), ''74,000 (II), and =66,000 (III) (Fig. 2B, lanes 5 and 7) . These correspond to DT-binding proteins having Mrs of -24,000, =16,000, and =8000, respectively. Taken together, these results demonstrate that minor differences exist in the 125I-labeled DT cross-linked surface proteins in Vero, DTs-II, and DTs-III cell extracts. However, since the cross-linked patterns from DTS-II and DTs-III cells were essentially identical (in Fig. 2A (Fig. 2) . The DT-binding proteins may represent differentially modified forms of the DT receptor or subunits of a receptor complex. If these proteins represent subunits of a receptor complex, they do not appear to be covalently linked by disulfide bonds since analyses of the cross-linked samples in the absence and in the presence of reducing agent were essentially the same (Fig. 2) . If there are subunits in the receptor complex, our results do not provide direct evidence that CD9 is one of the subunits since analysis of the cross-linked proteins derived from DTs-II and DTs-III cells appears essentially identical (Fig. 2A) anti-CD9 antibodies have been shown to protect cells against DT (10, 11) , we propose that this protection could be the result of steric hindrance due to binding of the antibodies to cell-surface CD9 epitopes in the vicinity of the DT receptor.
Except for the fact that CD9 is involved in platelet activation (19) , possibly due to its association with small GTPbinding proteins (20) , the role of CD9 is poorly understood.
